FIRST PHASE 2 RESULTS OF AUTOLOGOUS TUMOR-INFILTRATING LYMPHOCYTE (TIL; LN-145) MONOTHERAPY IN PATIENTS WITH ADVANCED, IMMUNE CHECKPOINT INHIBITOR-TREATED, NON-SMALL CELL LUNG CANCER (NSCLC)

JOURNAL FOR IMMUNOTHERAPY OF CANCER

BMJ PUBLISHING GROUP

1. Iovance Biotherapeutics, Inc. (San Carlos, CA, USA)